X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Hepzato kit (melphalan) is a combination drug/device product which administers melphalan directly to the liver through the HDS. It is approved for the treatment of metastatic uveal melanoma (mUM).
Lead Product(s): Melphalan
Therapeutic Area: Oncology Product Name: Hepzato Kit
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Alkeran (melphalan), is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects via filtration of the chemotherapeutic agent from the blood.
Lead Product(s): Melphalan
Therapeutic Area: Oncology Product Name: Alkeran
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., will continue to be the sole distributor for the sale of EVOMELA® (melphalan) for Injection in China.
Lead Product(s): Melphalan
Therapeutic Area: Oncology Product Name: Evomela
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Guokang Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 04, 2022
Details:
DARZALEX® SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous DARZALEX® (daratumumab).
Lead Product(s): Daratumumab,Bortezomib,Melphalan
Therapeutic Area: Oncology Product Name: Darzalex SC
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
Delcath intends to use the net proceeds of the offering for working capital and general corporate purposes including the continued development of Melphalan/HDS.
Lead Product(s): Melphalan
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $22.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
